CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. It offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dihydroxyphylline, theobromine, pentoxifylline, doxofylline, and biological enzymes; and h… Read more
CSPC Innovation Pharmaceutical Co Ltd Class A (300765) - Total Assets
Latest total assets as of September 2025: CN¥6.21 Billion CNY
Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) holds total assets worth CN¥6.21 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CSPC Innovation Pharmaceutical Co Ltd Class A - Total Assets Trend (2014–2024)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CSPC Innovation Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
CSPC Innovation Pharmaceutical Co Ltd Class A's total assets of CN¥6.21 Billion consist of 46.5% current assets and 53.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.5% |
| Accounts Receivable | CN¥561.81 Million | 9.3% |
| Inventory | CN¥398.67 Million | 6.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥225.21 Million | 3.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC Innovation Pharmaceutical Co Ltd Class A's current assets represent 46.5% of total assets in 2024, a decrease from 60.0% in 2014.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2024, down from 16.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 6.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 9.3% of total assets.
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of CSPC Innovation Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
CSPC Innovation Pharmaceutical Co Ltd Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CSPC Innovation Pharmaceutical Co Ltd Class A generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, CSPC Innovation Pharmaceutical Co Ltd Class A generates $ 0.89 in net profit.
CSPC Innovation Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 2.69 | 8.17 |
| Quick Ratio | 1.30 | 2.32 | 7.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.03 Billion | CN¥ 1.48 Billion | CN¥ 1.68 Billion |
CSPC Innovation Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between CSPC Innovation Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.12 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 6.9% |
| Total Assets | CN¥6.02 Billion |
| Market Capitalization | $1.53 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CSPC Innovation Pharmaceutical Co Ltd Class A's assets below their book value (0.25 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CSPC Innovation Pharmaceutical Co Ltd Class A's assets grew by 6.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2024)
The table below shows the annual total assets of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.02 Billion | +6.92% |
| 2023-12-31 | CN¥5.63 Billion | +22.86% |
| 2022-12-31 | CN¥4.58 Billion | +42.11% |
| 2021-12-31 | CN¥3.23 Billion | +9.17% |
| 2020-12-31 | CN¥2.95 Billion | +3.59% |
| 2019-12-31 | CN¥2.85 Billion | +105.09% |
| 2018-12-31 | CN¥1.39 Billion | +23.18% |
| 2017-12-31 | CN¥1.13 Billion | +16.56% |
| 2016-12-31 | CN¥968.68 Million | +1.22% |
| 2015-12-31 | CN¥957.02 Million | +15.05% |
| 2014-12-31 | CN¥831.82 Million | -- |